.2024 .. , : .
United Nations Office The .2025 .Breast Cancer Cases Projected to Rise by Nearly 40 Per Cent by 2050. , : .
Kuroda H. .2021 .Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. ” BMC Cancer, 21(1) : .
Jääskeläinen M.M. . .The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3+ and CD8+) and tumorassociated macrophages in early HER2+ breast cancer. ” Breast Cancer Research and Treatment, 201(2023) : 1-10.
Yazaki S. . .Integrative prognostic analysis of tumorinfiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1 and tertiary lymphoid structures in early-stage triple-negative breast cancer without adjuvant chemotherapy. ” Breast Cancer Research and Treatment, 197(2022) : 287-297.
Lin T. .2020 .Heat shock protein 90 family isoforms as prognostic biomarkers and their correlations with immune infiltration in breast cancer. , : 1-15.
Birbo B. .2021 .Role of HSP90 in cancer. International Journal of Molecular Sciences, 22(19) : 10317.
Hong L. .2024 .HSP90 promotes tumor-associated macrophage differentiation during triple-negative breast cancer progression. ” Scientific Reports, 14(1) : .
Safiri S. .2022 .Burden of female breast cancer in the middle East. , 80(1) : 1990-2019.
Feng J. .2022 .Peripheral blood lymphocyte subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer. ” Cancer Medicine, 11(15) : 2923-2933.
Sun Y.P. .2022 .Prognostic value of CD8+ tumor-infiltrating T cells in patients with breast cancer: A systematic review and meta-analysis. ” Oncology Letters, 25(1) : .
Li M. .2022 .Predictive and prognostic role of peripheral blood T-cell subsets in triple-negative breast cancer. ” Frontiers in Oncology, 12 : .
Luque M. .2022 .Tumor-infiltrating lymphocytes and immune response in HER2-positive breast cancer. ” Cancers, 14(24) : 6034.
Hamed M.M. .2022 .Evaluation of PD-L1, CD8 and CD20 as early predictive and tracking markers for breast cancer in Egypt. ” Heliyon, 8(5) : .
Rastogi S. .2024 .An update on the status of HSP90 inhibitors in cancer clinical trials. ” Cell Stress and Chaperones, 05(2024) : 519-539.
Falcone I. .2025 .HER2-driven breast cancer: Role of the chaperonin HSP90 in modulating response to trastuzumabbased therapeutic combinations. International Journal of Molecular Sciences, 26(14) : 6593.
Q. .2012 .Amplification and high-level expression of heat shock protein 90 mark aggressive phenotypes of human epidal growth factor receptor 2-negative breast cancer. ” Breast Cancer Research, 14(2) : .